Portage Biotech Inc. (PRTG)
Automate Your Wheel Strategy on PRTG
With Tiblio's Option Bot, you can configure your own wheel strategy including PRTG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRTG
- Rev/Share 0.0
- Book/Share 0.6459
- PB 5.2415
- Debt/Equity 0.02
- CurrentRatio 3.0767
- ROIC -4.1326
- MktCap 15517402.0
- FreeCF/Share -6.0037
- PFCF -2.4021
- PE -0.2626
- Debt/Assets 0.0103
- DivYield 0
- ROE -10.5554
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive Officer and Board Member Formerly Portage Biotech Inc. (Nasdaq: PRTG), Renamed AlphaTON Capital Corp with new ticker symbol “ATON” effective as of the opening of the market on September 4, 2025 Initial Financing to Acquire ~$100M TON tokens and Start Corporate Treasury; expected to close on or about September 5, 2025 DOVER, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (“AlphaTON Capital” or the “Company”, formerly Portage Biotech Inc.) …
Read More
Portage Biotech Stock Surges As It Prepares For Human Trial
Published: April 28, 2025 by: Benzinga
Sentiment: Positive
Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human trial preparations are underway.
Read More
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.
Read More
Why Is Portage Biotech Stock Skyrocketing Friday?
Published: March 28, 2025 by: Benzinga
Sentiment: Positive
Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
Read More
About Portage Biotech Inc. (PRTG)
- IPO Date 2002-01-02
- Website https://www.portagebiotech.com
- Industry Biotechnology
- CEO Alexander Pickett
- Employees 7